VYNE Therapeutics licenses BD2-selective BET inhibitors, selects development candidate VYN202

VYNE Therapeutics Inc.

$3.75M upfront payment for exclusive worldwide license; up to $68.75M in milestones plus tiered royalties.
VYN202 is oral BD2-selective BET inhibitor for immuno-inflammatory conditions; IND-enabling studies ongoing.
Preclinical data suggests VYN202 may be best-in-class with potent anti-inflammatory and anti-fibrotic effects.
IND filing planned by year-end; VYNE expects to advance VYN202 into clinical development.
VYNE also obtained rights to additional BD2-selective BET inhibitor compounds from Tay Therapeutics.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VYNE Therapeutics Inc. entered into License Agreement with Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) valued at up to an aggregate of $43.75 million (effective 2023-04-28).

Action: entry
Agreement: license
Counterparty: Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”)
Value: up to an aggregate of $43.75 million
Effective: 2023-04-28

Exact text from the filing

On April 28, 2023, VYNE Therapeutics Inc. (the “Company”) and Tay Therapeutics Limited (formerly known as In4Derm Limited, “Tay”) entered into a License Agreement (the “License Agreement”)

View on SEC.gov

Browse all material agreements →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-053593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.